Loading
Sonidegib (Odomzo) is the second hedgehog inhibitor for locally advanced basal cell carcinoma, similar in effect and side effects to vismodegib.
Sonidegib is an oral smoothened (SMO) antagonist that blocks hedgehog signalling, the pathway driven by PTCH1 or SMO mutations in nearly all basal cell carcinomas. It has a long half-life and high tissue distribution. In the BOLT trial (2015), 56% of patients with locally advanced BCC responded to the 200 mg dose, with responses that remained durable at 42 months of follow-up. It was approved in the US and EU in 2015 for locally advanced BCC that has recurred after surgery or radiation or in patients who are not candidates for those treatments, but not for metastatic disease. Its adverse effects are those of the class: muscle spasms, taste disturbance, hair loss and raised creatine kinase, which often lead to dose interruption. For a newcomer, sonidegib is the second hedgehog pill for advanced basal cell carcinoma and behaves much like vismodegib.
SMO antagonist blocking hedgehog signalling; long half-life and high tissue distribution. Connects to Smoothened (hedgehog pathway).
1.Sonidegib slips into a pocket on Smoothened (hedgehog pathway).
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE search: sonidegib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2015 | Locally advanced BCC recurrent after surgery or radiation, or not candidates |
| EU | 2015 | Same |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sonidegib" OR ABSTRACT:"Sonidegib" OR TITLE:"Odomzo" OR ABSTRACT:"Odomzo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sonidegib, not a curated reading list.
Shares PTCH1 (Patched 1), Patidegib, Medulloblastoma molecular groups (WNT, SHH, group 3, group 4), Hedgehog pathway inhibitors.
Shares Hedgehog pathway inhibitors, BOLT, Why people stop taking hedgehog inhibitors, Basal cell carcinoma (KEGG map).
Shares Patidegib, Hedgehog pathway inhibitors, Why people stop taking hedgehog inhibitors, Smoothened (hedgehog pathway).
Shares Hedgehog pathway inhibitors, BOLT, Why people stop taking hedgehog inhibitors, Smoothened (hedgehog pathway).
Shares PTCH1 (Patched 1), Hedgehog pathway inhibitors, BOLT, Why people stop taking hedgehog inhibitors.
Shares Hedgehog pathway inhibitors, Why people stop taking hedgehog inhibitors, Smoothened (hedgehog pathway), Locally advanced and metastatic basal cell carcinoma.
Shares Patidegib, Why people stop taking hedgehog inhibitors, Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma.
Shares Hedgehog pathway inhibitors, Locally advanced and metastatic basal cell carcinoma, Basal cell carcinoma, Small-molecule kinase inhibitors.